Evidence map›Paper›PMID 40661288›Full record

ArticlemedRxiv : the preprint server for health sciences2025

COVID-19 Vaccination Induces Cross-Reactive Dengue Antibodies with Altered Isotype Profiles and In Vitro ADE.

Sebastian Reinig, Chin Kuo, Sheng-Yu Huang, Kuei-Ching Hsiung, Po-Kai Chen, Etsuro Ito, Ing-Kit Lee, Ching-Yen Tsai, Shu-Min Lin, Shin-Ru Shih

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Sebastian ReinigResearch center for Emerging viral infections, Chang Gung University, Taoyuan, Taiwan.
Chin KuoResearch center for Emerging viral infections, Chang Gung University, Taoyuan, Taiwan.
Sheng-Yu HuangResearch center for Emerging viral infections, Chang Gung University, Taoyuan, Taiwan.
Kuei-Ching HsiungResearch center for Emerging viral infections, Chang Gung University, Taoyuan, Taiwan.
Po-Kai ChenDepartment of Biology, Waseda University, Tokyo, Japan.
Etsuro ItoDepartment of Biology, Waseda University, Tokyo, Japan.
Ing-Kit LeeDivision of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung,Taiwan.
Ching-Yen TsaiDivision of Infectious Disease, Department of Internal Medicine, Kaohsiung Municipal Feng-Shan Hospital, Kaohsiung, Taiwan.
Shu-Min LinDepartment of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University, School of Medicine, Taoyuan, Taiwan.
Shin-Ru ShihResearch center for Emerging viral infections, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0003-4874-401X

Funding

University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
NIAID NIH HHS U01 AI151698
6 · The paper itself

Abstract

Dengue virus is a mosquito transmitted flavivirus that cause inapparent or mild disease but can also cause severe hemorrhagic fever in humans. Cross-reactive IgG antibodies can cause under specific conditions antibody dependent enhancement (ADE) of the infection via Fc-receptor interaction. Antibodies from SARS-CoV-2 (anti-S) causing COVID-19 disease can also cross-react against the dengue envelope (anti-E). We therefore investigated the antibody profile of these cross-reactive antibodies and their ability to induce ADE. We found that the cross-reactive anti-E in COVID-19 vaccinated are dominated by IgM/A while, anti-S from vaccinated or anti-E from dengue infected patients have an IgG1 dominated antibody profile. The low-level anti-E IgG from COVID-19 vaccinated are dominated by low Fc-affinity IgG2/4 subclass. These antibodies were able to induce in vitro ADE stronger than from Dengue infected for the 1

Indexed as

antibody dependent enhancementCross-reactiveDengueisotype

Identifiers

PMID40661288
PMCPMC12258759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.